When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
Strategies to Relieve the Burden on Apheresis & Collection Centers
As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. View this on-demand webinar for an in-depth discussion of standardization strategies that can bring efficiencies to the apheresis and collection infrastructure. Also included is a Q&A session…
Critical Components for Developing & Managing Expansive, High-Performing Collection Networks
A high-performing collection center network is essential to providing and delivering quality starting material for emerging cell and gene therapies. Learn about effective practices for building and maintaining collection networks in our on-demand webinar, Critical Components for Developing & Managing Expansive, High-Performing Collection Networks. Amy Hines, BSN, RN, director, Collection Network Management, Be The Match BioTherapies®,…
How Starting Material Quality Impacts the Manufacturing and Success of Next-Generation Therapies
This on-demand webinar helps answer the question, “What constitutes quality allogeneic cell therapy starting material and how you can ensure it?” The webinar explores specific risks and practical downstream repercussions of insufficient and variable starting material quality. Our expert panelists discuss how to help ensure both high-quality and consistent cellular starting material by building efficiencies…
5 Considerations to Lower Your Risk When Selecting a Supply Chain Partner
As your therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity—and risk—increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain logistics partner. Keep these key considerations top of mind as you evaluate whether potential…
6 Considerations When Evaluating Cell Sourcing Partners
Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…
The Challenge of Multiple Audits and Redundant Training
As UCLA Health continues to participate in multiple CAR-T and other immunotherapy clinical trials, its apheresis unit and cell therapy lab continue to experience an increase in the need for their cell collection and processing services. Guest author, Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program, shares some of the…
Considerations for Developing Scalable and Efficient Collection Network Processes
On-demand webinar offers actionable insights as you develop your protocols. Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. When collection processes or protocols differ from those in place at a center, there are likely implications for training, forms and standard operating procedures. This…
Collection Capacity Impacts from Rapid Growth in Cell & Gene Therapy
The ONE Forum 2021: On-demand session As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. This session focuses on capability and capacity considerations to support these emerging therapies, standardization strategies and solutions that can bring efficiencies…